Skip to ContentSkip to Navigation
How to find us P. Meng


Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients

Oncogenic variants guiding treatment in thoracic malignancies

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients

Clinical value of EGFR gene amplifications detected using amplicon based targeted next generation sequencing data in lung adenocarcinoma patients

Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation

The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

An all-in-one transcriptome-based assay to identify therapy-related biomarkers in lung cancer

Detecting therapy-guiding aberrations in platelets and plasma at the transcriptome level in non-small-cell lung cancer

Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients

Read more